Pre-procedural antibody testing for SARS-CoV-2 in the routine endoscopic practice

• Alejandro Hernández Camba ^[1] ; Raquel Marcelino Reyes ^[1] ; Manuel Hernández-Guerra ^[2] ; Óscar Alberto Blasco Amato ^[1] ; Phillip Bennemann ^[1] ; Natalia De La Riva ^[1] ; Sara Diaz Machin ^[1] ; José Alejandro Medina ^[1]
  1. [1] Hospital Quironsalud Tenerife. Santa Cruz de Tenerife, Spain
  2. [2] Hospital Universitario Canarias. La Laguna, Santa Cruz de Tenerife. Spain
• Localización: Revista Española de Enfermedades Digestivas, ISSN-e 2340-4167, ISSN 1130-0108, Vol. 113, Nº. 2, 2021, págs. 116-118
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Methods: a retrospective multicenter cohort study was performed of all endoscopic procedures performed between April 27 and June 15, 2020. A screening questionnaire (SQ) was performed with patients three days prior to the procedure and 14 days after. Furthermore, a serologic SARS-CoV-2 test was performed 48 hours before. Results: two hundred and eleven consecutive patients with endoscopic procedures were included. No patients had a positive SQ, either on entry to the study or 14 days later. Only four patients (1.9 % [95 % CI: 0.07-4.8 %]) were positive for antibodies. Conclusion: the pre-endoscopy seroprevalence of SARS-CoV-2 is low in this cohort. Pre-procedural SARS-CoV-2 antibody testing does not add any benefit over clinical SQ to identify active COVID-19 patients.